#United States #San Diego #Genomics #Illumina #CSR

Illumina's 2024 Corporate Social Responsibility Report

Illumina Inc. has unveiled its annual Corporate Social Responsibility (CSR) Report for 2024, showcasing significant strides in enhancing the accessibility and affordability of genomic health services. The focus of this year’s report emphasizes the company's steadfast commitment to enhancing health equity through genomics, an urgent and vital mission in today's healthcare landscape.

Key Highlights from 2024

Illumina's focus on making precision health readily available to more people is reflected in various initiatives laid out in the report. The company successfully advocated for health care coverage for genomic testing, which has expanded by an astonishing 100 million people this year, elevating the total number of lives covered to a remarkable 1.4 billion globally. This move is indicative of Illumina's dedication to ensuring that genomic testing is not just a privilege but a right accessible to all, thereby driving health equity for underserved populations.

Additionally, Illumina has made significant strides in sustainability, boasting an impressive 80% reduction in packaging since 2019. This advancement aligns with the company's sustainability targets and is further enhanced by the introduction of the MiSeq i100 Series, characterized by its climate-friendly design. This product line achieved a 35% decrease in climate change impact, driven largely by innovations that allow for the room-temperature shipping and storage of its reagents.

Sustainable Operations

For the third consecutive year, Illumina reported that its global electricity consumption came entirely from renewable sources, reinforcing its commitment to sustainability. Achieving this milestone reflects Illumina's overarching plan to minimize its carbon footprint while maximizing health outcomes through innovative biotechnology.

Areas of Impact

The CSR report outlines four key impact areas where Illumina is making noticeable advancements:
1. Accelerating Access to Genomics: The launch of the MiSeq i100 Series highlights the commitment to improving access to genomic sequencing technology, streamlining the setup and analysis processes to make these tools more user-friendly.
2. Nurturing Our People and Communities: In a bid to strengthen its community footprint, 52% of Illumina employees participated in various volunteer programs, collectively contributing over 91,370 hours to philanthropic efforts. Moreover, the company has maintained a zero net pay gap for the sixth consecutive year, underscoring its dedication to equality in the workplace.
3. Integrating Sustainability: The company continues to implement measures that cut down emissions, achieving a 45% reduction in scopes 1 and 2 emissions, compared to its 2019 baseline. Furthermore, several Illumina laboratories are now recognized for their adherence to the highest sustainability standards, having completed the certification process with My Green Lab.
4. Operating Responsibly: Illumina emphasizes strong corporate governance practices, evidenced by 100% participation in third-party audit programs by its core facilities. The company has received favorable ratings from indices such as the Dow Jones Best-in-Class World Index, further illustrating its commitment to integrity and accountability.

Conclusion

As Illumina moves forward with its agenda of empowering people through the power of genomics, the company stands at the forefront of transforming precision health solutions. The 2024 CSR Report encapsulates its dedication to innovation, sustainability, and socio-economic equity, setting a high standard for the biotechnology industry. Interested readers can access the full report on Illumina's CSR website for more in-depth insights into the company’s initiatives and strategic directions. Follow Illumina on various social media platforms to stay updated on their ongoing efforts that align health advancement with environmental responsibility.

For more information, visit Illumina's Official Website.